Newly Announced Venture Capital Funds Underscore Strength of Canadian Biotech Sector

January 20, 2015

BIOTECanada welcomes the announcement by CTI Life Sciences of its new $134 million fund. CTI’s new fund combined with Canadian funds created in late 2014 by Versant Ventures ($305 million) and Teralys Capital ($279 million) makes available nearly three quarters of a billion dollars in new investment capital for Canada’s biotech sector. Read more

Share This Story


Investment capital is central to the biotechnology sector’s ability to take an innovative idea from the lab to commercial viability. Canada is home to hundreds of small, pre-commercial biotech companies at various stages of commercialization in all regions of the country.